A 96-Week, Phase IV, Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of EPZICOM Versus TRUVADA Administered in Combination With KALETRA in Antiretroviral-Naive HIV-1 Infected Subjects

Name: A 96-Week, Phase IV, Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of EPZICOM Versus TRUVADA Administered in Combination With KALETRA in Antiretroviral-Naive HIV-1 Infected Subjects
Creator: Vivli
Published: 2024-12-02 16:26:05
License: 暂无描述

DataCite Commons2024-12-02 更新2026-05-07 收录

下载链接：

https://search.vivli.org/doiLanding/studies/PR00009162/isLanding

下载链接

链接失效反馈

官方服务：

资源简介：

This study was designed to test the safety and effectiveness of EPZICOM(abacavir/lamivudine) and TRUVADA (emtricitabine/tenofovir) for the treatment of HIV infection when both are used in combination with KALETRA (lopinavir/ritonavir) over 96 weeks

提供机构：

Vivli

创建时间：

2023-08-15